A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.
BASECAMP-1 Trial Identifies Patients With Solid Tumors to Assess Novel CAR T-Cell Therapy
September 22nd 2023J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
2 Clarke Drive
Cranbury, NJ 08512